Brivaracetam (UCB 34714) is chemically related to levetiracetam (LEV, Keppra®). It
possesses a binding affinity for the synaptic vesicle protein 2A (SV2A) ten-fold above that of …

Background Fingolimod has shown reductions in clinical and MRI disease activity in patients
with relapsing-remitting multiple sclerosis. We further assessed the efficacy and safety of …

Background Narcolepsy type 1 is caused by severe loss or lack of brain orexin
neuropeptides. Methods We conducted a phase 2, randomized, placebo-controlled trial of …

Objective: To assess long-term safety and efficacy of fingolimod in patients with relapsing-
remitting multiple sclerosis (RRMS). Methods: Patients completing FTY720 Research …

Objective The 12-month (M), phase 3, double-blind, randomised TRANSFORMS study
demonstrated significant benefits of fingolimod 0.5 or 1.25 mg over interferon β-1a (IFNβ-1a) …

Objective: To evaluate immune responses in fingolimod-treated patients with multiple
sclerosis (MS) against influenza vaccine (to test for responses against anticipated novel …

Objective: We investigated the determinants and clinical correlations of MRI-detected brain
volume loss (BVL) among patients with relapsing-remitting multiple sclerosis from the phase …

Purpose: To evaluate the efficacy and tolerability of adjunctive brivaracetam (BRV), a novel
high‐affinity synaptic vesicle protein 2A ligand that also displays inhibitory activity at …

Objective: To investigate the effect of different natalizumab washout (WO) periods on
recurrence of MRI and clinical disease activity in patients switching from natalizumab to …

Background Fingolimod 0.5 mg once daily is the first approved oral therapy for relapsing
multiple sclerosis (MS). Objective To report integrated long-term safety data from phase 2/3 …